A retrospective analysis of genomic alterations in pure bladder adenocarcinoma and pure squamous-cell carcinoma, compared with the classical urothelial carcinoma, revealed similar opportunities for immunotherapy between urothelial carcinoma and squamous-cell tumors, whereas adenocarcinoma cases expressed immunotherapy biomarkers less frequently. The landscape of genomic alterations between these rare histologies was different.
Comprehensive Assessment of Immuno-oncology Biomarkers in Adenocarcinoma, Urothelial Carcinoma, and Squamous-cell Carcinoma of the Bladder
Necchi A.;
2020-01-01
Abstract
A retrospective analysis of genomic alterations in pure bladder adenocarcinoma and pure squamous-cell carcinoma, compared with the classical urothelial carcinoma, revealed similar opportunities for immunotherapy between urothelial carcinoma and squamous-cell tumors, whereas adenocarcinoma cases expressed immunotherapy biomarkers less frequently. The landscape of genomic alterations between these rare histologies was different.File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
